Acquisitions, NDA Filings, Key Findings, Conferences and Product Launches - Research Report on Perrigo, Forest Labs, Avanir Pharmaceuticals, Cubist Pharmaceuticals, and Dr. Reddy's Laboratories

NEW YORK, September 2, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Perrigo Co. (NYSE: PRGO), Forest Laboratories Inc. (NYSE: FRX), Avanir Pharmaceuticals (NASDAQ: AVNR), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Dr. Reddy's Laboratories Ltd. (NYSE: RDY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Perrigo Co. Research Report

On August 28, 2013, Perrigo Co. (Perrigo), along with Elan Corporation, plc. (Elan), announced that Perrigo Company Limited (New Perrigo) successfully filed a registration statement on Form S-4 in connection with Perrigo's proposed acquisition of Elan, which included a joint proxy statement of Elan and Perrigo (the Form S-4). Formerly announced on July 29, 2013, Perrigo and Elan signed a definitive agreement, under which New Perrigo will procure Elan in a stock-and-cash transaction valued at an estimated $8.6 billion (the Acquisition). The Full Research Report on Perrigo Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/4168_PRGO]

--

Forest Laboratories Inc. Research Report

On August 14, 2013 Forest Laboratories Inc. (Forest Labs) and Almirall, S.A. (Almirall) announced that they will defer the planned Q4 2013 submission of a New Drug Application (NDA) for the combination of aclidinium bromide, a long acting muscarinic antagonist and formoterol fumarate, a long acting beta agonist, for the purpose of indicating Chronic Obstructive Pulmonary Disease (COPD). The Company stated that the decision was made due to comments from the FDA at a recent pre-NDA meeting. According to Forest Labs, the delay related to resolving chemistry, manufacturing and control (CMC) specifications associated with the combination formulation. Forest Labs and Almirall are working with the FDA to address the CMC related comments given at the pre-NDA meeting to determine the future course of action, and it expects to provide an update when more data is available. Further, the Company said that this deferment decision does not affect the Tudorza (aclidinium bromide) monotherapy product. The Full Research Report on Forest Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ea24_FRX]

--

Avanir Pharmaceuticals Research Report

On August 22, 2013, Avanir Pharmaceuticals (Avanir) announced the publication of the findings from the PRISM patient registry in PLOS ONE, an international, peer-reviewed, open-access medical journal. PRISM was the largest registry ever conducted to deeply understand the prevalence and impact of pseudobulbar affect (PBA) in the United States. Randall Kaye, MD, Chief Medical Officer at Avanir commented, "The results from PRISM demonstrate that PBA symptoms are common among patients with diverse neurological conditions R. Higher CNS-LS scores were associated with significantly worse quality of life scores and greater use of antipsychotic/antidepressant medications. Publication of this important information will help healthcare practitioners better appreciate the frequency and multi-faceted impact of PBA symptoms in their neurologic patients." The Full Research Report on Avanir Pharmaceuticals - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2ee8_AVNR]

--

Cubist Pharmaceuticals Inc. Research Report

On August 28, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced that its CEO, Mike Bonney, will present at the Morgan Stanley Global Healthcare Conference, where he will review the Company's business activities, financial outlook, and current news. Cubist further informed that the event will take place at the Grand Hyatt New York hotel in New York City on September 9, 2013 at 3:50 p.m. ET. An audio-only presentation will be available via the Company website through the Investor Relations Conference Calendar section, and will be available for at least 30 days after the presentations. The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/92f2_CBST]

--

Dr. Reddy's Laboratories Ltd. Research Report

On August 22, 2013, Dr. Reddy's Laboratories Ltd. (Dr. Reddy's) announced that it has successfully launched Divalproex Sodium Extended - Release Tablets, USP (250 mg and 500 mg), a therapeutic equivalent of the generic version of Depakote ER (divalproex sodium) Tablet, Extended Release in the US market on August 19, 2013. The Company informed that the United States Food & Drug Administration (USFDA) approved Dr. Reddy's ANDA for Divalproex Sodium Extended- Release Tablets, USP. Further, according to an IMS Heath report, the Depakote ER brand and generic had combined U.S. sales of approximately $194 million MAT for the most recent twelve months ending in June 2013. The Full Research Report on Dr. Reddy's Laboratories Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ea85_RDY]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner